Pharmaceuticals

Anakinra Market Forecast 2025–2034: Where Businesses Should Invest Next

November 10, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Predicted Market Size Trajectory For The Anakinra Market From 2025 To 2034?

The anakinra market size has seen rapid expansion in recent years. It is projected to increase from $4.89 billion in 2024 to $5.46 billion in 2025, achieving a compound annual growth rate (CAGR) of 11.8%. The growth observed in the historical period can be attributed to the rising prevalence of rheumatoid arthritis, the approval of anakinra for treating rare autoinflammatory conditions like NOMID, increased awareness of biologics for managing chronic inflammatory conditions, and the growing adoption of targeted therapies.

The anakinra market is anticipated to experience significant expansion in the coming years. It is projected to reach $8.6 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 12.0%. This growth in the forecast period is primarily driven by the broadened applications of anakinra for various conditions, an increasing emphasis on personalized medicine, the rising occurrence of rare autoinflammatory disorders, advancements in drug delivery systems, and expanding healthcare access in emerging markets, which in turn boosts the demand for biologics. Key trends anticipated include the evolution of biosimilars and next-generation IL-1 inhibitors, the adoption of home-based and self-administered treatment solutions, strategic collaborations between biotech companies and academic institutions, and the integration of digital health solutions to enhance patient adherence.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21095&type=smp

Which Industry Drivers Are Expected To Accelerate The Anakinra Market From 2025 To 2029?

The growing prevalence of autoimmune disorders is projected to fuel the expansion of the anakinra market in the future. These disorders involve the body’s immune system mistakenly attacking and destroying its own healthy tissues and organs, perceiving them as threats. The increasing occurrence of autoimmune disorders stems from genetic susceptibility and environmental elements, including infections, pollution, and shifts in diet, which collectively contribute to their heightened frequency. Anakinra serves as a treatment for autoimmune disorders by inhibiting interleukin-1 (IL-1) activity, thereby alleviating inflammation in conditions such as rheumatoid arthritis, Still’s disease, and periodic fever syndromes. As an illustration, a report released in June 2024 by the Australian Institute of Health and Welfare, an Australian government body, indicated that during 2021–22, hospitalizations for rheumatoid arthritis reached 10,000, marking a 25% rise from 8,000 in the preceding year, which corresponds to a rate of 39 hospitalizations per 100,000 population. Consequently, the increasing prevalence of autoimmune disorders is propelling the expansion of the anakinra market.

What Are The Leading Segments Analyzed In The Anakinra Market?

The anakinra market covered in this report is segmented –

1) By Indication: Rheumatoid Arthritis, Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still’s Disease, Neonatal-Onset Multisystem Inflammatory Disease, Other Indications

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Wholesale Pharmacies

3) By End-User: Hospitals, Clinics, Homecare Settings

Subsegments:

1) By Rheumatoid Arthritis: Moderate-to-Severe Disease, Early-stage Disease

2) By Cryopyrin-Associated Periodic Syndromes: Muckle-Wells Syndrome, Neonatal-Onset Multisystem Inflammatory Disease

3) By Familial Cold Autoinflammatory Syndrome: Acute Episodes, Chronic Symptoms

4) By Systemic Juvenile Idiopathic Arthritis: Active Systemic Disease, Inactive Disease With Flares

5) By Adult-Onset Still’s Disease: Active Disease, Remission Induction

6) By Neonatal-Onset Multisystem Inflammatory Disease: Acute Disease Episodes, Long-term Disease Management

7) By Other Indications: Gouty Arthritis, Osteoarthritis, Spondyloarthritis

Which Ongoing Trends Are Expected To Shape The Anakinra Market Outlook?

Major companies within the Anakinra market are securing regulatory approvals to broaden the approved uses for new therapeutic applications. These regulatory approvals signify formal authorizations from government agencies, enabling a drug to be marketed and prescribed for specific medical conditions after an evaluation of its safety, efficacy, and quality. For instance, in November 2022, the Food and Drug Administration, a US government agency, granted Emergency Use Authorization (EUA) for Kineret (anakinra) to treat hospitalized adults with COVID-19-related pneumonia requiring supplemental oxygen, aiming to mitigate the risk of severe respiratory failure. This authorization was founded on the SAVE-MORE phase 3 study, which demonstrated that early treatment with Kineret improved patient outcomes. Kineret functions by blocking the cytokines IL-1a and IL-1ß, which contribute to the hyperinflammatory response observed in severe COVID-19 cases. While it does not hold full FDA approval for this indication, it is authorized for temporary use during the public health emergency.

Which Leading Companies Dominate The Anakinra Market Share?

Major companies operating in the anakinra market are Swedish Orphan Biovitrum AB, Boehringer Ingelheim, Amgen Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/anakinra-global-market-report

What Are The Key Regional Factors Influencing The Anakinra Market Growth?

North America was the largest region in the anakinra market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anakinra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Anakinra Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21095&type=smp

Browse Through More Reports Similar to the Global Anakinra Market 2025, By The Business Research Company

Arthritis Monoclonal Antibodie Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/arthritis-monoclonal-antibodie-global-market-report

Psoriatic Arthritis Treatments Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/psoriatic-arthritis-treatments-global-market-report

Companion Animal Arthritis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/companion-animal-arthritis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795